Introduction
Patients with Parkinson's disease (PD) are consistently reported to be underweight compared with healthy subjects [1] . Weight loss (WL) may begin several years prior to the clinical diagnosis [2] in association with various factors, including PD-associated hyposmia, dysphagia, difficulties in self-feeding, intestinal hypomotility, depression, cognitive impairment, anorexia and nausea, as well as with increased energy expenditure due to rigidity, tremor and levodopa-induced dyskinesia [1, 3] .
Multiple pieces of evidence suggest a key role for WL as a biomarker of disease progression in PD and other neurodegenerative disorders [4, 5] . In fact, body mass index (BMI) [calculated as weight (kg) divided by height (m 2 )] is a strong predictor of survival in PD [4, 5] . Moreover, WL correlates with several nonmotor complications directly associated with poor PD functional status, such as cognitive impairment and orthostatic hypotension [3] .
In previous studies, we found that patients with PD treated with levodopa/carbidopa intestinal gel (LCIG) infusion may be particularly susceptible to WL. Causative factors for this phenomenon, however, remain partially unclear and are likely to be related to a multifactorial interplay between intestinal malabsorption, global deterioration of the overall clinical conditions and a possible effect of dopaminergic medications on appetite [6, 7] .
The main aim of this study was to evaluate prevalence and severity of WL occurring during LCIG treatment and to analyze the association between the nutritional status of patients with PD undergoing LCIG and motor and non-motor indices of PD disability progression.
Patients and methods
Inclusion criteria were idiopathic PD (as per the UK Brain Bank criteria [8] ), treatment with LCIG for at least 6 months and availability of weight measurement before starting LCIG. Exclusion criteria were signs or symptoms suggestive of atypical parkinsonism, bariatric surgery, poor general health and medical conditions potentially associated with pathological WL, such as gastroenteric disorders, malignancies, thyroid dysfunction, etc.
As primary endpoints, we measured changes in body weight and BMI between T0 [about 1 week (range 1-7 days) before starting LCIG] and T1 (last outpatient visit on LCIG therapy). Secondary endpoints included the Mini Nutritional Assessment (MNA) , an 18-item questionnaire based on anthropometric measurements, eating habits, psychological and functional aspects associated with nutrition specifically validated for nutritional assessment of community and institutionalized elderly patients [9] ; Edinburgh Feeding Evaluation in Dementia Questionnaire (EdFED-Q), an 11-item clinical questionnaire assessing behaviours of feeding difficulty (e.g. refusing to eat, turning head away while being fed, spitting out food), nursing intervention (e.g. supervision, physical help) and patient passivity during meals (e.g. spillage, leftover) [10] ; Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part II, part III and UPDRS part IV; Mini Mental State Examination; Beck Depression Inventory; Schwab and England scale of activities of daily living; and levodopa equivalent daily dose (LEDD), calculated as per a validated conversion table [11] (LEDD/kg). Items 32 and 33 of the UPDRS were used to assess the duration and severity of dyskinesia, and item 2.3 of the MDS-UPDRS was used to rate the severity of dysphagia. Validated conversion tables were applied to convert data from the UPDRS part II and III to the MDS-UPDRS part II and III, when needed [12] .
All patients were evaluated for peripheral neuropathy (PNP), defined as symmetric alteration of action potential amplitudes or velocities in at least two motor or sensory nerves on nerve conduction studies [13] . PNP was classified as 'subclinical' when presenting with electrophysiological alteration not accompanied by clinical symptoms.
Ethical committee approval was obtained (CS2/535; protocol number 0006409) and patients provided written informed consent.
Statistical analysis
Continuous variables were described as mean AE SD and categorical variables were described as frequencies or percentages. Changes in body weight between T0 and T1 were calculated as per the following formula: (Δkg [T0-T1]/body weight at T0) * 100). Correlation analyses were carried out using a two-step approach. First, a Pearson's rank correlation coefficient was applied. Data showing significant correlation at univariate analysis were then selected as independent variables in a multiple linear regression model adjusting for PD duration and LCIG treatment duration. Two-tailed P-values <0.05 were considered statistically significant. Analyses were carried out using SPSS 24.0 (SPSS, Chicago, IL, USA).
Results
We enrolled 44 patients, corresponding to 82% of the entire population (n = 54) in active treatment with LCIG at our center. Exclusions were due to poor general health (n = 3 cases), LCIG duration <6 months (n = 3 cases), lack of data at T0 (n = 2 cases), detention in prison (n = 1 case) and diagnostic revision into multiple system atrophy (n = 1 case). The duration of LCIG therapy was 51.6 AE 28.5 (range 10-120) months. Clinical, demographic and nutritional data are detailed in Table 1 .
There was an average WL of 9.9 AE 10.5% between T0 and T1, corresponding to a weight change of >10 kg, in 12 patients (27%), between 6 and 10 kg in 12 patients (27%), and between 2 and 5 kg in six patients (13%). No significant weight changes were observed in the remaining 14 patients.
At T1, 19 patients (43%) had a BMI < 22 kg/m 2 (which is considered the threshold for undernutrition in the elderly population), 9 (21%) met the criteria for malnutrition (MNA score < 17) and 6 (14%) required nocturnal enteral feeding to supplement their dietary intake.
Motor complications (UPDRS-IV) improved due to a reduction in the severity of wearing-off, whereas no significant changes were observed in the duration and severity of dyskinesia ( Table 1 ). The prevalence of PNP increased between T0 and T1, with eight cases of subclinical PNP becoming 'symptomatic' and eight cases with normal neurophysiological examination developing a subclinical PNP (P = 0.001; Table 1 ). The dose of dopaminergic therapies significantly increased between T0 and T1 (P = 0.002).
A direct correlation was observed between the extent of WL and the percentage of waking day spent with dyskinesia (b = 0.381; P = 0.006) and between MNA score and the following variables: Hoehn Yahr stage (b = 0.287; P = 0.012), dysphagia severity (b = 0.227; P = 0.007), MDS-UPDRS-III total score at T1 (b = 0.320; P = 0.009), EdFED-Q total score (b = 0.320; P = 0.008) and LEDD/kg (b = 0.290; P = 0.002) ( Table 2 ). Patients developing clinical or subclinical PNP between T0 and T1
showed a worse nutritional status (P = 0.005) but not a greater WL.
Discussion
The complex relationship between food intake and weight changes in PD remains unclear. Regardless of food intake, patients with PD have lower BMI than healthy subjects [14] . Moreover, a decrease in BMI correlates with a more aggressive pattern of motor symptom progression [4] , suggesting that PD-associated body weight changes are not necessarily due to reduced caloric intake but may rather correlate with underlying disease mechanisms. The relationship between WL and PD is even more complex in patients undergoing LCIG. In a previous study, we found that 17% of patients treated with LCIG developed a WL > 10 kg over a 2-year observational period [6] . Significant changes in body weight were also reported by other authors. Sensi et al. described an average WL of 14.7% (10.8 kg) over a 6-year follow-up in patients treated with LCIG, Antonini et al. reported a WL of 6.7% over 24 months and Buongiorno et al. reported a WL of 7% over 22 months [6, [15] [16] [17] .
To the best of our knowledge, this is the first study specifically investigating factors associated with body weight changes in patients with PD with long-term exposure to LCIG. We found that 68% of patients developed mild to severe WL after 4.5 AE 2.3 years, 27% had a WL > 10 kg and 21% met the criteria for malnutrition. After adjusting for LCIG duration, the duration of dyskinesia was the only factor associated with WL, whereas severity of motor symptoms, dysphagia and dose of dopaminergic medications correlated with the nutritional status.
Overall, we observed a prevalence and severity of WL that were relatively higher compared with other studies [7, 16, 17 ], possibly reflecting the greater level of attention devoted to body weight, an outcome frequently neglected or relegated to the role of ancillary measure. However, we cannot exclude the influence of factors such as the long follow-up duration and the inclusion of patients in an advanced stage of disease. Interestingly, we did not find any correlations between WL and disease severity, expressed as motor disability (i.e. Schwab and England scale, Hoehn Yahr stage, MDS-UPDRS-III or ΔMDS-UPDRS-III score), cognitive or neuropsychological impairment (Mini Mental State Examination, Beck Depression Inventory and MDS-UPDRS items 1.1-1.5 score) and peripheral nervous system involvement. Instead, we observed an association between WL and the percentage of the waking day spent with dyskinesia. A post hoc analysis of our data suggests that an adjustment in the dose of dopaminergic therapies for body weight changes might be required to minimize dyskinesia due to a relative increase in LEDD/kg, which may ultimately worsen the severity of peak-dose dyskinesia with increased energy expenditure and consequent WL [3, 18] . Also, the relatively low score observed on the EdFED-Q indicates that WL was primarily due to increased energy expenditure rather than feeding difficulties.
As WL does not necessarily imply malnutrition [19] , we used the MNA to investigate factors primarily contributing to the nutritional status. Overall, we observed that 43% of patients were at risk of malnutrition and 21% were undernourished. These data are in line with the published literature, which reports a 0-24% prevalence of malnutrition in PD, depending on the study methodology and definition criteria [20] . Interestingly, we found that dyskinesia alone is not a determinant of nutritional status, whereas disease severity (expressed as Hoehn Yahr stage and MDS-UPDRS-III score), dysphagia, feeding difficulties (expressed as EdFED-Q score), dosage of dopaminergic therapies (expressed as LEDD/kg) and developing or worsening of a pre-existing PNP correlate with the nutritional state. These data confirm the association between late-stage PD and malnutrition [20] . It is of relevance that six of our patients successfully used the PEG-J (AbbVie, North Chicago, IL, USA) tube to supplement their daily food intake with nocturnal enteral feeding. Additionally, in spite of the symptomatic LCIG effect on off-time reduction, our data indicate that this device-aided treatment seems to have no beneficial effect on the underlying neurodegenerative disease effect of PD, at least with regard to two possible markers of disease progression, i.e. WL and malnutrition. However, this speculation should be confirmed by a case-control study. Finally, an effect of LCIG on the intestinal flora and production of gut hormones affecting hunger cannot be excluded. Small intestinal bacterial overgrowth has been reported to be more common among patients with PD compared with controls [21] . Small intestinal bacterial overgrowth has been associated with a severe pattern of PD symptoms, motor complications and axial disability, as well as with a possible malabsorption of dopaminergic medications [22] . Although the interaction between LCIG and small intestinal bacterial overgrowth has not yet been investigated, specific studies seem to be required when considering the possible susceptibility to changes in the microbiota composition of patients receiving a therapy delivered though a feeding tube and the high frequency of gastrointestinal symptoms observed in association with LICG.
In summary, our data highlight the importance of devoting specific attention to and conducting periodic assessments of nutrition in patients undergoing LCIG. The assessment of patients with PD developing WL should include the evaluation of different possible causes, not only related to dyskinesias or motor complications, but also to dysphagia, cognitive impairment, hallucinations, apathy, depression and self-feeding difficulties, which should always be considered in advanced PD. The possibility of nocturnal enteral feeding should also be contemplated as an effective option in LCIG-treated patients with PD, as a feeding tube is already available [23] .
Several limitations should temper the strength of our conclusions, including the retrospective analysis of data collected as part of an open-label observational study and the lack of a control group treated with oral levodopa. Our main aim, however, was to investigate the prevalence and severity of WL in patients undergoing LCIG treatment rather than comparing LCIG and oral levodopa treatments.
Conclusions
Weigh loss may occur in over 60% of patients with PD undergoing LCIG. Special attention is required in patients with dyskinesia, which might account for an increased energy expenditure. Clinicians should also consider that the nutritional status of patients with PD is independently related to indices of disease progression such as motor symptom severity and dysphagia. Periodic nutritional assessments seem to be required to identify patients who could benefit from additional enteral feeding. In addition, a reduction in the LCIG dose might be required to adjust for changes in the LEDD/kg ratio in patients developing WL.
